Pendulum Therapeutics

Pendulum Therapeutics is a biotechnology company focused on improving metabolic health by targeting the gut microbiome. The company develops and markets medical probiotics, which are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.

The company's flagship product is Pendulum Glucose Control, a medical food designed to help manage blood sugar levels in people with type 2 diabetes. This product is a blend of five specific strains of beneficial bacteria, including Akkermansia muciniphila, which has been shown to be important for gut health. The company also offers other probiotic and synbiotic products targeting various aspects of gut and metabolic health, such as GLP-1 Probiotic, Metabolic Daily, and Polyphenol Booster.

Pendulum Therapeutics operates on a direct-to-consumer business model, selling its products through its website. The company also offers a subscription-based membership program that provides customers with regular deliveries of its products at a discounted price. The company's target market includes individuals with type 2 diabetes, prediabetes, and those looking to improve their overall metabolic and gut health.

The company's products are backed by scientific research, including clinical studies that have been published in peer-reviewed journals. Pendulum Therapeutics has also established strategic partnerships with other companies in the nutrition and health space, such as a partnership with Fonterra, a global nutrition science leader.

Keywords: medical probiotics, microbiome, metabolic health, type 2 diabetes, gut health, Akkermansia, direct-to-consumer, e-commerce, biotechnology, clinical research